A 68-year-old Japanese womanwas admitted to our hospital in September
Introduction
With the recent advances in imaging techniques, it has becomepossible to detect intrahepatic small masses of less than 2 cm in diameter. Ultrasonography (US) guided tumor biopsy allows for pathological diagnosis of very small lesions. Hepatocellular carcinoma (HCC) combined with cholangiocellular carcinoma is sometimes encountered (1) , but cases of double cancers of combined HCCand intrahepatic cholangiocellular carcinoma (ICC) are very rare. Weherein describe a patient with heterochronous double cancer, in whoma pathological diagnosis of ICC was made based on the tumor biopsy specimen, and a clinical diagnosis of HCCwas made based on imaging findings and serum tumor marker such as alpha-fetoprotein (AFP).
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Case Report
A 68-year-old Japanese womanwas admitted to our hospital for evaluation in September 1995, because of a mass detected in the subsegment 7 of right liver lobe (S7) by US (Fig.  1A ) during a follow-up examination for hepatitis B virus (HBV). The womanhad been identified as an HBVcarrier 5 years earlier. Twoyears prior she had undergone cholecystectomy for gallbladder stones. She had no history of jaundice, blood transfusion, alcohol abuse, or exposure to hepatotoxins. Uponadmission, laboratory data were as follows: aspartate aminotransferase (AST), 19 IU// (normal <35 IU//); alanine aminotransferase (ALT), 5 IU// (normal <3 1); and indocyanine green 15-minute serum retention test (ICG R15) 10% (normal <10%). Hepatitis B surface antigen (HBsAg), anti-hepatitis B virus envelope antibody (HBeAb), and anti-hepatitis B virus core antibody (HBcAb) were positive; anti-hepatitis B surface antibody (HBsAb), hepatitis B virus envelope antigen (HBeAg), and anti-hepatitis C antibody (HCVAb)were negative. Her serum AFP level was 67 ng/ml (normal range, <20 ng/ml). Repeat USdisclosed a hypoechoic mass in S7. Hepatic angiography disclosed faint hypervascular staining in the same area (Fig.  IB) . Dynamic computed tomography (CT) also showed this lesion (Fig. 1C) . Early-phase contrast CTshowed a well en-Double Cancer of Combined HCCand ICC Figure 1A -E. A: A low echoic mass (arrow) in subsegment 7 of the liver was detected by abdominal ultrasonography, B: a fine staining (arrow) by commonhepatic arterial angiography, C: a low density mass was detected by plain computed tomography, D: a mass lesion was centrally enhanced in the early phase of contrast mediuminfusion, E: the enhancement disappeared in the late phase of contrast medium infusion in September 1995.
hanced tumor in S7, 2.0x1.5 cm in diameter (Fig. ID) ; latephase contrast CT showed a low density area (Fig. IE) . Under a diagnosis of HCC,percutaneous ethanol injection therapy (PEIT) (2, 3) was carried out for the tumor in S7 in October 1995 after informed consent was obtained from her. Thereafter, PEITs were repeated twice within a week. The total injected ethanol was 15 ml. Twoweeks after PEITs, her serum AFPfell to 7.8 ng/ml, when contrast CT did not show tumor enhancement ( Fig. 2A-C) .
The patient did well for 3 years. However, a considerable elevation in serum AFP(159 ng/ml) was noted in an outpatient visit in November 1998. Subsequent US disclosed a round mass in S7 measuring 2.5x1.7 cm and demonstrating a mosaic pattern. Contrast-enhanced early-phase CT demonstrated a central high density area (Fig. 3B) ; a low density area was seen at late phase (Fig. 3C) . Under a diagnosis of recurrent HCC, the patient was admitted to our hospital for the second time, and PEITs were performed four times after informed consent was obtained from her. The total injected ethanol was 7.5 ml. Two weeks after PEITs, her serum AFP fell to 68.0 ng/ml, when contrast CT did not show tumor enhancement ( Fig. 4A-C) . She was free from recurrence for 9 months. However, follow-up USdemonstrated an irregular low echoic mass in the subsegment 3 of the left liver lobe (S3) in August 1999 (Fig. 5) . She was admitted to our hospital for the third time. Physical examination upon this third admission showed no abnormality. Serumliver function tests were within normal range, except for increased carbohydrate antigen 19-9 (CA19-9) (420 U/ml; normal range, <37 U/ml). Serum hepatitis B virus markers were the sameas those at the first admission. CTshoweda low density mass with an irregular margin in S3. Plain CT demonstrated a low density mass, 2.0x2.0 cm in diameter (Fig. 6A) . Contrast CTshowed centrally faint enhancement at the early phase (Fig. 6B ) and a central low density area with remaining marginal enhancement at the late phase in S3 (Fig. 6C) . Preoperative ultrasonic cardiography (UCG) showed moderate to severe aortic regurgitation (AR). Weexplained the possibility of malignant tumor in the liver and a risk in regard to the partial hepatectomy. Since we were not able to obtain her informed consent for the partial hepatectomy, the S3 mass was treated by radio frequency interstitial tissue ablation (RITA® , 50 W, 100°C, for 10 minutes), which has a possibility of cure (4, 5), other than surgical resection, immediately after tumor biopsy in October 1999. Four weeks after RITA®her serum CA19-9 had fallen remarkably to 180 U/ml, and serum AFP was 7.0 ng/ml, when contrast CT did not show tumor enhancement (Fig.   7A-C) .
The patient has remained well for 6 months. In February 2000, her serum AFP and CA19-9 levels were 2 ng/ml and 83 U/ml, respectively, when contrast CT did not show tumor enhancement ( Fig. 8A-C) .
Microscopic tumor biopsy specimen findings Biopsy specimens were fixed in 10% formalin and processed for light microscopy. Paraffin-embedded tissue blocks were sectioned. After deparaffinization, the sections were stained with hematoxylin and eosin (HE stain). The S3 tumor consisted almost entirely of lumina of the glandular structures (Fig. 7A) . The tumor cells exhibited large nuclei and abundant cytoplasm. The atypical glands were covered with several layers of cuboidal epithelium with prominent nucleoli. These findings were indicative of moderately differentiated tubular adenocarcinoma. No HCCwas demonstrated in the tumor biopsy specimen (Fig. 9B) . 
Immunohistochemistry tumor biopsy specimen findings
For immunohistochemical studies, the avidin-biotin complex (ABC) method was used. Antibodies were used for the following: AFP (Histofine; Nichirei, Tokyo), CEA (Campaign, IBL, Fujioka, Japan), CA19-9 (NS19-9; Centocor, PA, USA). On immunohistochemical examination, ICC tumor showed CEAand CA19-9 to be positive, but AFP was negative.
Discussion
Combined HCCand ICC has been described in the following three categories: 1) separate masses composed of either HCCor ICC, 2) contiguous masses composed of independent HCCand ICC elements, and 3) a mass with intermingling HCC and ICC components (1) . In Japan, these three types are known as double cancer, combined-type HCCand ICC, and mixedtype HCCand ICC, respectively (6) . The present case fits the double cancer category. The HCCand ICC were located in different lobes (S7 and S3) and were identified heterochronously (4-year interval). Therefore, HCCand ICC have been recognized as the double cancer type as mentioned by Raymondand James, although ICC was pathologically diagnosed and HCC was not. The incidence of double cancer in the liver is much lower than that of combined cancer, which is also rare (7) . There are reports that only two cases of double cancer (0.5%) among a total of 367 adult patients with HCCand/or ICC who were surgically resected during 14.5 years (8) , and that only one of five combined cases was double cancer, and that only one case was double cancer of HCCand ICC in an atrophied cirrhotic liver among their 393 consecutive autopsied cases (9) . Wefound only two reports on heterochronous double cancer of HCCand ICC (1, 10) .
HCCis known to be closely associated with chronic HBV or HCVinfection (1 1). The development of ICC was generally unrelated to hepatitis viral infection. Recently, infection with HCVor HBVhas been suggested to be involved in the pathogenesis of ICC (12, 13) . In the Japanese literature (14, 15) , some patients with nodular ICC were included, and all of them were positive for HCVAbor HBeAgand were diagnosed as HCC.Since the tumor biopsy specimen came from within a part of the tumor (obtained by needle biopsy), mixed-type HCC and ICC could not be completely ruled out in the present case. However, serum CA19-9 levels are generally reported to be high in patients with ICC but not in patients with mixed-type HCCand ICC (16) , and serum CA19-9 levels were increased in our patient despite the tumor's small size. Therefore, the S3 mass was thought to be an ICC. It is thought that patients with intrahepatic gallstone have a risk for development of ICC (17) . In our case, intrahepatic gallstone was not detected by several examinations, although she suffered from gallbladder stones 6 years prior to the occurrence of ICC. In our case, the development of ICC might be related to HBVinfection. US was most useful in detecting the small mass; late enhanced CT (15) played an important role in the differential diagnosis of HCCand ICC, and angiography was also helpful in making a diagnosis of HCC. US guided tumor biopsy is possible to obtain a pathological diagnosis that is definitive. With improved imaging, double liver cancer may be diagnosed with increasing frequency.
It is thought that the best therapy for ICC is surgical resection. There is one report in which ICC was treated with PEIT, and the patient has remained well (10). We performed RITA® immediately after tumor biopsy because we thought the S3 mass was a mixed-type HCCand ICC. It was only later that we recognized this lesion as an ICC. Weadvised her to receive partial hepatectomy after pathological diagnosis revealed ICC. However, we were not able to obtain her informed consent because she had moderate to severe ARand partial hepatectomy was a risk, as explained by the anesthesiologist. Therefore, we are following-up this patient very carefully. She continues to do well. RITA®might be a useful strategy for small ICC, but a careful and long-term observation is imperative.
